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to lower efficacies and increased the proportion of subjects shedding resistant viruses. As an 
example, a 75-mg/day prophylaxis regimen initiated 2 days before inoculation and stopped 2 days 
after inoculation would decrease the efficacy to 18% and increase the proportion of subjects shedding 
resistant virus to 8%. Conclusions: Using a simulation model based on H1N1 infection data, we were 
able to reproduce drug-resistant emergence rates similar to those reported in the literature. Based on 
our simulation results, we recommend that current prophylaxis regimens should be avoided to limit 
resistance emergence. Initiation of treatment during the incubation period should be restricted to 
subjects prone to develop severe cases and should use high doses (at least 150 mg per intake) and 
frequent intakes (bid or tid) for a longer period (10-15 days) in order to decrease the risk of resistant 
virus emergence and to preserve high efficacies. 
P1-278 
Susceptibility of influenza B viruses to neuraminidase inhibitors: findings from 
the first 4 years (2008–2012) of the global Influenza Resistance Information 
Study (IRIS) 
E van der Vries1*, D Ip2, V Reed3, X Tong4, K Wojtowicz3, CA Boucher1 
1Erasmus MC, Rotterdam, the Netherlands; 2The University of Hong Kong, Hong Kong SAR, China; 
3Micron Research Ltd, Ely, United Kingdom; 4F. Hoffmann-La Roche, Inc, Nutley, New Jersey, United 
States 
Background: Type B influenza virus infections continue to account for a substantial proportion of 
clinical illness. Little is known about comparative disease profiles by virus lineage. A global 
observational trial (the Influenza Resistance Information Study or IRIS; NCT00884117) was initiated 
to study neuraminidase inhibitor (NAI) susceptibility and the clinical and virological course of influenza 
in treated and untreated patients. Materials and Methods: Patients in the northern and southern 
hemispheres (USA, France, Germany, Poland, Norway, Hong Kong, Australia) with influenza-like 
illness and/or a positive rapid influenza test result were enrolled. Throat/nasal swabs were performed 
on Days 1, 3 (self-swab), 6 and 10 and tested for influenza A and B viruses by RT-PCR. Influenza-
positive samples collected on Days 1, 6 or 10 were cultured and subsequently sequenced (HA and 
NA) and phenotypically tested for NAI susceptibility. The lineage of B viruses was determined from 
sequencing. Clinical information, including the scoring of seven influenza symptoms (scale: 0 
[absent], 1 [mild], 2 [moderate], 3 [severe]), was recorded on diary cards by the patient or the patient’s 
legal guardian (Days 1–12). Symptoms were also assessed by the investigator at each visit. The 
decision to prescribe an NAI was left to the physician’s discretion. Results: In the first 4 years of IRIS 
(December 2008 to March 2012), 2262 influenza-positive (RT-PCR) patients were enrolled, of whom 
697 presented with a type B influenza virus infection (564 Victoria, 98 Yamagata, 35 undetermined 
lineage). Most type B patients (402; 58%) were children aged < 13 years. A total of 330 (47%) type B 
patients were treated with oseltamivir (as monotherapy) within 2 days of symptom onset; a further 26 
started oseltamivir 2 days after symptom onset. Eleven patients received zanamivir, one received 
amantadine and another received rimantidine. A total of 328 (47%) did not receive any influenza 
antiviral. Symptoms were mild to moderate on Day 1 (mean total score: 12.8, treated; 12.9, 
untreated), and the mean temperature on Day 1 was 38.2°C. All viruses obtained at baseline or post-
baseline were susceptible to NAIs: mean (SD) IC50 values for oseltamivir were 4.8 nM (2.5 nM) and 
5.5 nM (2.3 nM) for the Victoria and Yamagata viruses, respectively; the corresponding values for 
zanamivir were 2.0 nM (1.4 nM) and 2.9 nM (1.6 nM), respectively. No known NAI resistance 
mutations were detected by NA or HA population sequencing. The proportion of RT-PCR–positive 
patients on Day 6 was 130/309 (42.1%) for patients treated with oseltamivir and 152/312 (48.7%) for 
untreated patients. In Kaplan–Meier analyses, no significant differences in median time to influenza 
RNA clearance were found between oseltamivir-treated and -untreated patients, either in adults or 
children. The time to symptom resolution (all symptom scores ≤ 1) was 5 days (95% CI, 4–5 days) in 
oseltamivir-treated children and 6 days (95% CI, 5–6 days) in untreated children (P = .026), but no 
significant difference in symptom resolution time was found in adults (Kaplan–Meier analysis). 
Conclusions: Analysis of type B influenza viruses obtained globally between 2008 and 2012 showed 
that all pre-treatment B/Victoria and B/Yamagata viruses were susceptible to oseltamivir and 
zanamivir. Moreover, no resistant viruses were detected during treatment. Given the non-randomised 
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design of this study, no definitive conclusions can be drawn with regard to the clinical benefit of 
oseltamivir in patients infected with type B influenza viruses. 
P1-279 
Persistence of influenza A(H3N2) viruses following oseltamivir therapy in 
nursing homes in the Netherlands 
A Meijer1*, P Overduin1, F Kerpiclik2, Y van Weert2, M-J Veldman-Ariesen2, on behalf of the Centre for 
Infectious Disease Control Influenza Antiviral Therapy and Prophylaxis Study Group 
1National Institute for Public Health and the Environment, Centre for Infectious Disease Control, 
Centre for Infectious Disease Research, Diagnostics and Screening, Bilthoven, the Netherlands; 
2National Institute for Public Health and the Environment, Centre for Infectious Disease Control, 
Centre for Infectious Disease Epidemiology and Surveillance, Bilthoven, the Netherlands 
Background: Influenza viral load dynamics and emergence of antiviral resistance during oseltamivir 
therapy and prophylaxis have mainly been studied in previously health adults and children and 
immunocompromised individuals with influenza. This information is sparse on one of the main target 
populations for antiviral use if influenza prevention by vaccination fails: frail elderly residing in nursing 
homes. Therefore, we analysed specimens from nursing home residents in the Netherlands collected 
during oseltamivir therapy and prophylaxis. In addition, we aimed to assess transmission of (antiviral 
resistant) viruses by virus sequence analysis. Materials and Methods: The study was performed 
during the 2011/2012 and 2012/2013 winter seasons. Oseltamivir therapy was offered to residents 
with influenza-like illness (ILI) with or without laboratory diagnostic results. Oseltamivir prophylaxis 
was offered to residents without respiratory symptoms as soon as influenza virus infection in another 
resident was confirmed by laboratory testing. From residents on therapeutic use, specimens 
(combined nose and throat swabs) were requested at the start and end of therapy (day 5). From 
residents on prophylaxis, end-of-prophylaxis specimens were requested (day 10). RT-PCR–positive 
specimens were further characterised by virus isolation and phenotypic antiviral susceptibility assay; 
sequencing of the haemagglutinin (HA), neuraminidase (NA) and matrix protein genes directly from 
the clinical specimen; and single nucleotide polymorphism (SNP) real-time RT-PCR for detection of 
mutations resulting in oseltamivir reduced susceptibility–associated amino acid substitutions E119V 
and R292K in the NA of A(H3N2) viruses. Results: Of 49 residents with ILI, start-of-therapy 
specimens were obtained, 33 of which were positive for A(H3N2) influenza virus. An end-of-therapy 
specimen was obtained from 37 residents, 10 of which were positive for A(H3N2) influenza virus. 
Paired specimens were available for 28 residents, of whom 19 were confirmed to be infected with 
A(H3N2) influenza at the start of therapy. One of these 28 residents had an A(H3N2)-positive 
specimen only at the end of therapy. Twelve of nineteen residents (63%) had cleared the infection 
upon resampling, whereas 7 of 19 residents (37%) had A(3N2)-positive specimen at both the start 
and end of therapy. In five of these cases, the viral load decreased (mean Ct increase of 6.9; range 
4.1-9.8), whereas in two cases the viral load increased (Ct decreases of 2.1 and 4.3). By the end of 
therapy, one resident with a decreasing viral load was shedding a virus containing the R292K amino 
acid substitution, whereas the start-of-therapy specimen contained 292R. NA sequence analysis, 
SNP detection and phenotypic analysis did not show emergence of viruses with a resistance marker 
or reduced inhibition by oseltamivir for the other six residents with positive end-of-therapy specimens. 
Of 32 residents who received oseltamivir prophylaxis, 1 was found positive for A(H3N2) influenza 
virus at day 5 following development of ILI and 2 were found positive for influenza virus type B lineage 
B/Yamagata/16/88 at day 10 (end of prophylaxis). Sequence analysis of the M protein of 17/43 
detected A(H3N2) viruses showed a subset of viruses with the S31N and V27I amino acid substitution 
M2-blocker resistance markers, which is a unique combination. Uniqueness was confirmed by 
mutations in the NA and HA genes of these viruses compared with those of other sequenced 
A(H3N2) viruses. These unique viruses originated from two locations of one nursing home about 5 km 
apart. Conclusions: The high proportion of A(H3N2)-positive end-of-therapy specimens (37%) 
suggests that a 5-day course of oseltamivir therapy for nursing home residents may not be adequate 
to clear the influenza virus completely. Nevertheless, the R292K substitution in the NA of the 
influenza virus was found for only one resident receiving oseltamivir therapy, suggesting a relatively 
high barrier for the A(H3N2) virus to attain this or other substitutions associated with reduced 
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